Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Italy ETF (EWI) vs Novavax Inc (NVAX) Price & Performance

Ishares Msci Italy ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Italy ETF vs Novavax Inc — how do they compare? Ishares Msci Italy ETF trades at $63.12, while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Ishares Msci Italy ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

EWINVAX
Sector
Broad Market / FactorHealth
52-Week High
$63.35$11.19
52-Week Low
$50.31$6.22
Market Cap
$1.31B
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Italy ETF

EWI trades at $63.165, showing minimal daily movement with a slight decline of 0.01%. The technical outlook is bullish based on moving averages, though oscillators signal neutrality with RSI readings above 80 indicating potential overbought conditions. Recent news highlights Italy's market strength with EWI hitting a 52-week high in June 2026, driven by improving industrial data and recovery narrative. A dividend of $1.17 is scheduled for June 2026, providing income appeal.

The stock benefits from positive European market sentiment and Italy's economic recovery, but faces risks from ECB rate policy and energy price volatility. Technical indicators suggest near-term consolidation may be needed given overbought signals. Long-term prospects appear favorable if Italy's economic momentum continues, though investors should monitor ECB decisions and energy market developments closely.

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Returns comparison

Trailing returns across standard periods

About Ishares Msci Italy ETF

EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.

Read more on EWI

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX